Eptinezumab Demonstrated Efficacy in Sustained Prevention of Episodic and Chronic Migraine Beginning on Day 1 After Dosing.

Headache · 2020 · PMC7756794 · PMID 33165938

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

nominally significantno p-value reported

In the current analysis, the timing of treatment onset was determined by finding the first day from which a treatment effect was nominally significant and sustained without interruption through the end of the first dosing interval (week 12).

also in 7,732 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.